Harpoon_logo (002).jpg
Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022
December 05, 2022 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
22157.jpg
CAR-T Cell Therapy Global Market Report 2022: Ever-Surging Rates of Cancer Deaths Fuels Adoption
November 30, 2022 08:33 ET | Research and Markets
Dublin, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapy Market by Target Indications, Target Antigens, Key Players and Key Geographies - Global Forecast 2022-2035" report has been added to...
Patient with recurrent high-grade glioma treated with TVAX Immunotherapy
TVAX Biomedical Announces Receipt of $2 Million FDA Orphan Products Grant for Glioblastoma Study
October 18, 2022 10:07 ET | TVAX Biomedical
OLATHE, Kan., Oct. 18, 2022 (GLOBE NEWSWIRE) -- TVAX Biomedical (TVAX) is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. In September...
Harpoon_logo (002).jpg
Harpoon Therapeutics Appoints Luke Walker, M.D., as Chief Medical Officer
October 04, 2022 07:30 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the...
Knowmade 2
mRNA Cancer Therapies Patent Landscape 2022: Featuring BioNTech, Moderna, Novartis, Sanofi & Others
October 04, 2022 04:03 ET | Research and Markets
Dublin, Oct. 04, 2022 (GLOBE NEWSWIRE) -- The "mRNA Cancer Therapies Patent Landscape 2022" report has been added to ResearchAndMarkets.com's offering. For nearly three decades, extensive efforts...
Harpoon_logo (002).jpg
Harpoon Therapeutics Appoints Lauren Silvernail to Board of Directors
September 19, 2022 16:05 ET | Harpoon Therapeutics
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced...
Global Engineered T Cells Market
Global Engineered T Cells Market Report 2022-2027: Increasing Demand for Innovative Biopharmaceutical Therapies & Recent Advances in CAR-T Cell Engineering Propelling Sector
August 11, 2022 08:48 ET | Research and Markets
Dublin, Aug. 11, 2022 (GLOBE NEWSWIRE) -- The "Global Engineered T Cells Market (2022-2027) by Type, Application, End User, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff...
22157.jpg
Global CAR-T Therapy Market Report 2022-2026 & 2031: Focus on Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA
August 03, 2022 06:03 ET | Research and Markets
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Therapy Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global CAR-T therapy market is expected to...
Global T-Cell Immunotherapy Market
Global T-Cell Immunotherapy Market Report to 2027 - Featuring Atara Biotherapeutics, Autolus and bluebird bio Among Others
July 21, 2022 07:18 ET | Research and Markets
Dublin, July 21, 2022 (GLOBE NEWSWIRE) -- The "T-Cell Immunotherapy Market Intelligence Report - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering. The Global...
Harpoon_logo (002).jpg
Harpoon Therapeutics Expands Leadership Team
July 06, 2022 07:30 ET | Harpoon Therapeutics
Appointments named for two key executive leadership positions in human resources and translational medicine SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc....